[Asia Economy Reporter Eunmo Koo] Nivec has signed contracts with six multinational pharmaceutical companies for anticancer therapeutic substances at the world's largest international bio-healthcare conference.
On the 21st, Nivec announced that at the 'JP Morgan Healthcare Conference,' it signed Material Transfer Agreements (MTA) and Confidential Disclosure Agreements (CDA) with six multinational pharmaceutical companies regarding anticancer therapeutics and the peptide platform (NIPEP-TPP) applied to anticancer treatments. They plan to send related data and materials after mutual consultation on specific supply timings.
Through the 'Corporate Partnering' meetings at this JP Morgan Conference, Nivec discussed collaboration plans such as technology licensing and material supply contracts with up to 15 global pharmaceutical companies, including Germany's Beiersdorf. The company explained that significant achievements were made in key pipeline collaborations, including meetings with Germany's Boehringer Ingelheim on liver and lung fibrosis, Japan's Eisai Pharmaceutical on inflammatory bowel disease, and China's Chilu Pharmaceutical on osteoporosis treatments.
Nivec also conducted technology presentations and partnering meetings at the 'Biotech Showcase 2020' held at Union Square in San Francisco, USA.
A company representative stated, "At the Biotech Showcase, Nivec received considerable attention for presentations on its peptide platform technology and five new drug pipelines, including osteoporosis treatments. During the US conference schedule, relatively concrete discussions were held with several global pharmaceutical companies regarding follow-up milestone payments and detailed contract periods, and we expect to achieve visible results within this year."
Earlier this year, Nivec received its first order along with an official supply contract for preclinical candidate substances from one of the global top five pharmaceutical companies. At this conference, follow-up discussions related to this included issues concerning protein manufacturing and supply for two preclinical candidate substances, including tumor therapeutics. Nivec stated, "Along with discussions on the progress of research on specific tumor and other disease treatments, we also conducted commercial contract negotiations regarding milestone scales and contract periods, achieving substantial verbal agreements."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
